Thomas V. Riley

18.3k total citations · 3 hit papers
353 papers, 13.5k citations indexed

About

Thomas V. Riley is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Thomas V. Riley has authored 353 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Infectious Diseases, 143 papers in Epidemiology and 47 papers in Molecular Biology. Recurrent topics in Thomas V. Riley's work include Clostridium difficile and Clostridium perfringens research (216 papers), Microscopic Colitis (108 papers) and Viral gastroenteritis research and epidemiology (95 papers). Thomas V. Riley is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (216 papers), Microscopic Colitis (108 papers) and Viral gastroenteritis research and epidemiology (95 papers). Thomas V. Riley collaborates with scholars based in Australia, United Kingdom and United States. Thomas V. Riley's co-authors include Christine Carson, Katherine A. Hammer, Daniel R. Knight, Brian J. Mee, Barbara J. Chang, Claudia Slimings, Deirdre A. Collins, Briony Elliott, David L. Paterson and R.A. Bowman and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Thomas V. Riley

340 papers receiving 12.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of Action ofMelaleuca alternifolia(Tea Tree) Oil onStaphylococcus aureusDetermined by Time-Kill, Lysis, Leakage, and Salt Tolerance Assays and Electron Microscopy

2002 775 citations Christine Carson, Brian J. Mee et al. profile →
Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia

1995 517 citations Christine Carson, Thomas V. Riley profile →
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis

2013 424 citations Claudia Slimings, Thomas V. Riley Journal of Antimicrobial Chemotherapy profile →

Peers

Countries citing papers authored by Thomas V. Riley

Since Specialization

Citations

This map shows the geographic impact of Thomas V. Riley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas V. Riley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas V. Riley more than expected).

Fields of papers citing papers by Thomas V. Riley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas V. Riley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas V. Riley. The network helps show where Thomas V. Riley may publish in the future.

Co-authorship network of co-authors of Thomas V. Riley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas V. Riley. A scholar is included among the top collaborators of Thomas V. Riley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas V. Riley. Thomas V. Riley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High prevalence of Clostridioides difficile in retail garden products from two Australian states 2025 ·Anaerobe ·(unknown), Craig A. Bell, (unknown), Su‐Chen Lim, Simon Reid, Linda Selvey, Thomas V. Riley	0
2	Clostridioides difficile in Australian dairy farms 2025 ·Anaerobe ·Su‐Chen Lim, (unknown), Deirdre A. Collins, (unknown), Craig A. Bell, Linda Selvey, (unknown), Thomas V. Riley	0
3	Clostridioides difficile is a bacterial priority pathogen 2025 ·Anaerobe ·Wiep Klaas Smits, Kevin W. Garey, Thomas V. Riley, Stuart Johnson	1
4	Clostridioides ( Clostridium ) difficile infection in hospitalized adult patients in Cambodia 2025 ·Microbiology Spectrum ·(unknown), Deirdre A. Collins, Kefyalew Addis Alene, Sotharith Bory, (unknown), (unknown), Shu Meng, (unknown), Archie C. A. Clements, Thomas V. Riley	1
5	Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017 2022 ·Microbial Genomics ·Korakrit Imwattana, Papanin Putsathit, Deirdre A. Collins, (unknown), Pattarachai Kiratisin, Thomas V. Riley, Daniel R. Knight	9
6	Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update 2021 ·Journal of Antimicrobial Chemotherapy ·Claudia Slimings, Thomas V. Riley	42
7	A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile 2021 ·Microbial Genomics ·Korakrit Imwattana, César Rodríguez, Thomas V. Riley, Daniel R. Knight	20
8	Positional Isomers of Biphenyl Antimicrobial Peptidomimetic Amphiphiles 2021 ·ACS Medicinal Chemistry Letters ·(unknown), Papanin Putsathit, Thomas V. Riley, Paul A. Keller, Stephen G. Pyne	9
9	Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model 2021 ·Antibiotics ·(unknown), (unknown), (unknown), Papanin Putsathit, M. Hutton, Katherine A. Hammer, Daniel R. Knight, Thomas V. Riley, Dena Lyras, Paul A. Keller, Stephen G. Pyne	8
10	Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015–18 2021 ·Journal of Antimicrobial Chemotherapy ·Papanin Putsathit, (unknown), Narelle George, (unknown), (unknown), Tony M. Korman, Despina Kotsanas, Monica M Lahra, Rodney McDougall, (unknown), (unknown), Graeme R. Nimmo, (unknown), Jennifer Robson, Lynette Waring, Michael C. Wehrhahn, Gerhard F. Weldhagen, Richard Wilson, Thomas V. Riley, Daniel R. Knight	16
11	Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: synthesis, antibacterial evaluation and preliminary mechanism of action studies 2019 ·European Journal of Medicinal Chemistry ·(unknown), Papanin Putsathit, Katherine A. Hammer, Steven M. Wales, Daniel R. Knight, Thomas V. Riley, Paul A. Keller, Stephen G. Pyne	29
12	Reducing length of stay to improve Clostridium difficile-related health outcomes 2018 ·Infection Disease & Health ·David Brain, Adrian Barnett, Laith Yakob, Archie C. A. Clements, Thomas V. Riley, Kate Halton, Nicholas Graves	8
13	Economic evaluation of interventions designed to reduce Clostridium difficile infection 2018 ·PLoS ONE ·David Brain, Laith Yakob, Adrian Barnett, Thomas V. Riley, Archie C. A. Clements, Kate Halton, Nicholas Graves	6
14	Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound 2018 ·Scientific Reports ·(unknown), Daniel R. Knight, Scott G. Stewart, Allan J. McKinley, Thomas V. Riley, Katherine A. Hammer	14
15	Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages 2016 ·Journal of Clinical Microbiology ·Michelle Cairns, Mark D. Preston, Christopher L. Hall, Dale N. Gerding, Peter M. Hawkey, Hiroo Kato, Heejung Kim, Ed J. Kuijper, Trevor D. Lawley, Hanna Pituch, Siobhán Reid, Brian Kullin, Thomas V. Riley, Katie Solomon, Perng‐Jy Tsai, J. Scott Weese, Richard A. Stabler, Brendan W. Wren	44
16	First report of Erysipelothrix rhusiopathiae‐associated septicaemia and histologic changes in cultured Australian eels, Anguilla reinhardtii (Steindachner, 1867) and A. australis (Richardson, 1841) 2014 ·Journal of Fish Diseases ·(unknown), (unknown), (unknown), (unknown), Thomas V. Riley	10
17	Survey of the Antimicrobial Activity of Commercially Available Australian Tea Tree ( Melaleuca alternifolia ) Essential Oil Products In Vitro 2011 ·The Journal of Alternative and Complementary Medicine ·(unknown), (unknown), Katherine A. Hammer, Christine Carson, Per Mølgaard, Thomas V. Riley	24
18	Legionella longbeachae in Western Australian potting mix (Letter) 1997 ·The Medical Journal of Australia ·(unknown), Brian J. Mee, Thomas V. Riley	2
19	Susceptibility of Staphylococcus saprophyticus to heavy metals 1992 ·UWA Profiles and Research Repository (University of Western Australia) ·(unknown), Thomas V. Riley	1
20	Isolation ofClostridium difficilefrom stored specimens and comparative susceptibility of various tissue culture cell lines to cytotoxin 1986 ·FEMS Microbiology Letters ·R.A. Bowman, Thomas V. Riley	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact